BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | Jun 3, 2020
Finance

Pfizer’s $500M public biotech fund to complement late-stage BD activity

Pfizer is bolstering future business development opportunities with a $500 million fund designed to take small to mid-cap public biotechs with early-stage clinical assets to their next inflection points. Pfizer Inc. (NYSE:PFE) Group President and...
BioCentury | Jun 1, 2020
Product Development

Ibrance failure in adjuvant breast cancer opens door for Novartis, Lilly

The failure of Pfizer’s second-best-selling drug Ibrance in a pivotal trial as an adjuvant treatment for breast cancer opens a window for rival drugs in an indication that could have been a major growth opportunity...
BioCentury | May 30, 2020
Politics, Policy & Law

WHO launches COVID-19 patent pool into headwinds

The World Health Organization launched its COVID-19 patent pool Friday facing significant obstacles that include a lack of support from China, the U.K. and the U.S., as well as pushback from leading pharma executives who...
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 28, 2020
Product Development

Pharma leaders warn vaccine manufacturing doesn’t turn on a dime

Don’t expect global manufacturing capacity to rapidly fill in for the first few COVID-19 vaccines to market, according to Paul Stoffels. The J&J vice chairman and CSO said it could take over a year for...
BioCentury | May 28, 2020
Finance

Fresh off Lilly deal, AbCellera readies to deploy $105M to streamline antibody-based R&D

Days after expanding a deal with Eli Lilly, AbCellera has raised $105 million in a series B round to speed its partners’ path to the clinic by expanding its own R&D capabilities. CEO Carl Hansen...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

Now that investors have demonstrated demand for biotech IPOs that has led to a warm reception for new listings over the past few weeks, the queue has begun to grow again, as a handful of...
BioCentury | May 23, 2020
Management Tracks

New look at the top for WuXi AppTec

WuXi AppTec has named Steve Yang as co-CEO and Edward Hu as vice chair and chief investment officer. WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) promoted Steve Yang to co-CEO from EVP and CBO. He joins...
BioCentury | May 22, 2020
Politics, Policy & Law

Woodcock steps away from CDER for Operation Warp Speed; Marks back to CBER

In a major reorganization intended to better align FDA’s activities with the national effort to develop COVID-19 countermeasures, Janet Woodcock is temporarily stepping away from her position as director of FDA’s Center for Drug Evaluation...
Items per page:
1 - 10 of 9765
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | Jun 3, 2020
Finance

Pfizer’s $500M public biotech fund to complement late-stage BD activity

Pfizer is bolstering future business development opportunities with a $500 million fund designed to take small to mid-cap public biotechs with early-stage clinical assets to their next inflection points. Pfizer Inc. (NYSE:PFE) Group President and...
BioCentury | Jun 1, 2020
Product Development

Ibrance failure in adjuvant breast cancer opens door for Novartis, Lilly

The failure of Pfizer’s second-best-selling drug Ibrance in a pivotal trial as an adjuvant treatment for breast cancer opens a window for rival drugs in an indication that could have been a major growth opportunity...
BioCentury | May 30, 2020
Politics, Policy & Law

WHO launches COVID-19 patent pool into headwinds

The World Health Organization launched its COVID-19 patent pool Friday facing significant obstacles that include a lack of support from China, the U.K. and the U.S., as well as pushback from leading pharma executives who...
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 28, 2020
Product Development

Pharma leaders warn vaccine manufacturing doesn’t turn on a dime

Don’t expect global manufacturing capacity to rapidly fill in for the first few COVID-19 vaccines to market, according to Paul Stoffels. The J&J vice chairman and CSO said it could take over a year for...
BioCentury | May 28, 2020
Finance

Fresh off Lilly deal, AbCellera readies to deploy $105M to streamline antibody-based R&D

Days after expanding a deal with Eli Lilly, AbCellera has raised $105 million in a series B round to speed its partners’ path to the clinic by expanding its own R&D capabilities. CEO Carl Hansen...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

Now that investors have demonstrated demand for biotech IPOs that has led to a warm reception for new listings over the past few weeks, the queue has begun to grow again, as a handful of...
BioCentury | May 23, 2020
Management Tracks

New look at the top for WuXi AppTec

WuXi AppTec has named Steve Yang as co-CEO and Edward Hu as vice chair and chief investment officer. WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) promoted Steve Yang to co-CEO from EVP and CBO. He joins...
BioCentury | May 22, 2020
Politics, Policy & Law

Woodcock steps away from CDER for Operation Warp Speed; Marks back to CBER

In a major reorganization intended to better align FDA’s activities with the national effort to develop COVID-19 countermeasures, Janet Woodcock is temporarily stepping away from her position as director of FDA’s Center for Drug Evaluation...
Items per page:
1 - 10 of 9765